Merck & Co Inc. (MRK) News Headlines

▮ More

Date

Headline

2/15/2019 7:01:28 AM Merck: FDA Grants Priority Review To Its Supplemental BLA For KEYTRUDA With Inlyta For Advanced RCC

2/14/2019 6:48:33 AM Merck To Present Data From Three Cohorts Of Phase 1b/2 KEYNOTE-365 Study

2/5/2019 6:57:16 AM Merck: FDA To Review Regulatory Filings By Company For Two Antibacterial Agents

2/5/2019 6:47:14 AM Merck: FDA Accepts For NDA Review For Combination Of Imipenem/Cilastatin And Relebactam, And SNDA For ZERBAXA

2/4/2019 6:59:26 AM Merck Gets Positive CHMP Opinion For Keytruda In Combination With Chemotherapy

2/4/2019 6:46:45 AM Merck Says CHMP Of EMA Adopted Positive Opinion Recommending KEYTRUDA In Combination With Chemotherapy

2/1/2019 7:30:12 AM Merck Q4 Results Beat Estimates

2/1/2019 6:50:57 AM Merck & Co Inc. Q4 adjusted earnings Beat Estimates

2/1/2019 6:45:42 AM Merck Q4 GAAP EPS $0.69; Non-GAAP EPS $1.04

1/30/2019 6:55:40 AM Merck Receives FDA Breakthrough Therapy Designation For V114 - Quick Facts

1/30/2019 6:46:29 AM Merck Receives FDA Breakthrough Therapy Designation For V114

1/30/2019 2:19:45 AM Biotech Stocks Facing FDA Decision In February

1/29/2019 4:31:12 PM Merck Elects Mary Ellen Coe To Board Of Directors

1/29/2019 3:11:48 PM Merck & Co Inc. (MRK) Declares Quarterly Dividend of $ 0.55, Record Date 3/15/2019

1/23/2019 5:49:08 AM Merck, Tencent Sign Deal On Intelligent Digital Healthcare Services In China

1/3/2019 6:56:10 AM Merck's KEYTRUDA Gets Five New Approvals In Japan

1/3/2019 6:48:10 AM Merck Says KEYTRUDA Receives Five New Approvals In Japan

1/3/2019 6:36:59 AM Merck Exercises Option For NGM Biopharma's Investigational Insulin Sensitizer

1/3/2019 6:32:14 AM Merck Exercises Option For NGM Bio’ Investigational Insulin Sensitizer, NGM313, For Treatment Of NASH And Type2 Diabetes

1/2/2019 6:35:56 AM BriaCell Therapeutics Announces Imminent Clinical Use Of New Novel, Frozen Formulation For Bria-IMT